Advertisement

Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma

      Evidence for the efficacy of combined therapy with sorafenib and radiotherapy in the treatment of locally advanced hepatocellular carcinoma is lacking. Results from limited prospective/retrospective studies regarding toxicity and response of combinational therapy are discordant. By using our multi-institutional electronic medical research database, we compared the effectiveness of concurrent radiotherapy and targeted therapy versus radiotherapy alone for locally advanced hepatocellular carcinoma.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.